Experimental evaluation reveals potent anticancer activity of T-1-PA by targeting EGFR, suggesting therapeutic potential.
Key Points
T-1-PA demonstrated a potent inhibitory effect on EGFR with an IC₅₀ of 0.736 μM, promoting anticancer activity.
In vitro assays indicated T-1-PA effectively inhibited the proliferation of HepG2 and MCF7 cells, yielding IC₅₀ values of 0.88 μM and 1.13 μM, respectively.
Computational analyses, including molecular docking and ADMET profiling, confirmed T-1-PA's strong binding affinity and favorable drug-like properties.
Induction of apoptosis and cell cycle arrest in HepG2 cells through EGFR inhibition suggests T-1-PA's significant therapeutic promise.